Skip to main content
Premium Trial:

Request an Annual Quote

BioSilta Collaborates with KTH Stockholm

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — The KTH Royal Institute of Technology said today it will use screening technology from Finnish start-up BioSilta Oy for KTH's Human Protein Atlas project.

YouDoBio was also named as the distributor of BioSilta products in Sweden and Denmark.

Terms for neither deal were disclosed.

BioSilta's EnBase technology will be used to accelerate secondary screening of previously poor expressing candidates for the Human Protein Atlas project. In a statement, the two firms said they have been collaborating to optimize protein screening using microwell plates and BioSilta's enzymatic release media technology.

“By combining our knowledge we have been table to develop a very reliable screening method used to determine if a protein could be successfully expressed or not,” KTH professor and Director of Protein Science Sophia Hober said in a statement. KTH is based in Stockholm, Sweden.

“We see a great potential in the EnBase technology and hope other research groups also will find this product beneficial,” Hober added.

BioSilta is based in Oulu, Finland and uses enzymes and biocatalytic activity to advance cell culture technology.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.